Abstract
Purpose: Preclinical and clinical data support the studyof polar-planar compounds such as N-Methylformamide (NMF) inadvanced squamous cell carcinoma of the uterine cervix (SCC).This phase II trial sought to determine the efficacy andtoxicities of NMF in patients with advanced SCC. Patientsand methods: Eligibility for this trial requiredbidimensionally measurable squamous or adenosquamous cellcancer of the uterine cervix incurable by surgery or radiationtherapy, ECOG performance status of ≤2, no prior NMF and nomore than one prior chemotherapy regimen. Patients receivedNMF at 2000 mg/m2 intravenously over 15–30 minutes days 1,8 and 15. The cycle was repeated every 42 days. A single doseescalation of 25%, 500 mg/m2 was made after the firstcycle if the toxicities did not exceed grade I for hepatictoxicity and grade II for nausea and vomiting. Results:From July 1987 through September 1998, 21 patients withadvanced squamous cell carcinoma of the uterine cervix wereentered on study. Two patients were ineligible because therewas no pretreatment SGOT on one and the other deterioratedprior to drug approval. Therefore, 19 patients were include inthe analysis of response and survival. Four were inevaluable,3 due to inappropriate tumor evaluation and I secondary tograde III vomiting, who went off study. These patients wereincluded in the denominator while computing the results. Therewere 2 deaths, one due to pulmonary hemorrhage fromperforation during central venous insertion and one due todisease. 30% (6/19) patients had toxicities, EasternCooperative Oncology Group (ECOG) grade III or higher and 2 ofthese patients suffered multiple grade III toxicities. Therewere no complete or partial responses. Conclusion: Inthis population, NMF in the dose and schedule employedexhibited no clinical activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schottenfeld H, Fraumeni JF, Jr. eds: Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford Press, 1996.
Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics. 1997. Ca Cancer J Clin 47: 5–27, 1997
Eifel PJ, Berek JS, Thigpen JT: Cancer of the Cervix, Vagina, and Vulva. In DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 5th ed. Philadelphia, PA: Lippincott-Raven, 1997, pp 1433–1478
Asbury RF, Blessing TA, Soper JT: A GOG phase II study of Amonafide (NSC# 308847) in squamous cell carcinoma of the cervix. Am J Clin Oncol 17(2): 125–128, 1994
Smith HO, Stringer CA, Kavanagh JJ, Gershenson DM, Edwards CL, Wharton JT: Treatment of advanced and recurrent squamous cell carcinoma of the uterine cervix with mitomycin-c, bleomycin and cisplatinum chemotherapy. Gynecol Oncol 48: 11–15, 1993
Cordeiro RF, Savarese M: Role of glutathizone depletion in the mechanism of action of N-Methylformamide and N_cimethylformaldamide in cultured human colon carcinoma cell lines. Cancer Res 46: 1297–1305, 1986
Moon RC, Mehta RG, Rao KUN: Retinoids and cancer in experimental animals. In Sporn MB, Roberts AM, Goodman DS, (eds), The Retinoids: Biology, Chemistry and Medicine, 2nd edn. New York: Raven Press, 1994, pp 573-595
Clarke CA, Philips FS, Sternberg SS: Effects of NMethylformamide and related compounds in sarcoma 180.Proc Soc Exp Bio Med 84: 203–207, 1953
Braunsteiner H: Antileukamische Wirkung von N-Methylformamide. Klin Wochenschrift 32: 611–612, 1954
Potter M, Law WL: Studies of a plasma-cell neoplasm of the mouse. I. Characterization of neoplasm 70429, including its sensitivity to various antimetabolites with the rapid development of resistance to azaserine, DON, and NMF. JNCI 18: 413–441, 1957
Marks PA, Rifkind RA: Differentiation modifiers. Cancer 54: 2766–2769, 1984
Marks P, Richon VM, Kiyokawa H, Rifkind RA: Inducing differentiation of transformed cells with hybrid polar compounds: A cell cycle dependent process. Proc Natl Acad Sci 91: 10251–10254, 1994
Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks P: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci 93: 5705–5708, 1996
National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mc-Fadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655, 1982
Phase I minutes:Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, NCI, June 1983
Wienmann MC, Cummings FJ: Phase I clinical and pharmacological trial of oral NMF. Proc AM Soc Clin Oncol 4: 38, 1985 (abstr)
Ettinger DS, Orr DW, Rice AP: Phase I study of NMF in patients with advanced cancer. Cancer Treat Rep 69: 489-493, 1985
O'Dwyer PJ, Donehower M, Sigman LM: Phase I trial of NMF. J Clin Oncol 3: 853–857, 1985
McVie JG, ten Bokkel Huinink WW, Simonetti G et al: Phase I trial of NMF. Cancer Treat Rep 68: 607–610, 1984
Verweij J, Klijn JGM, Planting ASTh, et al: NMF in metastatic colorectal cancer: a phase II study. Fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy, October 22-24, 1986 (abstr 2.12)
Meyskens Fl Jr, Surwit E, Moon TE et al: Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 86: 539, 1994
Weiss GR, Liu PY, Lippman SM et al: 13-cis-Retinoic Acid or All-trans-Retinoic Acid plus Interferon alpha in Recurrent Cervical Cancer: A Southwest Oncology Group Phase II Randomized Trial. Gyn Onc 71: 386–390, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rajdev, L., Yu, ZF., Wadler, S. et al. N-Methylformamide in Advanced Squamous Cancer of the Uterine Cervix: An Eastern Cooperative Oncology Group Phase II Trial. Invest New Drugs 19, 233–237 (2001). https://doi.org/10.1023/A:1010672618269
Issue Date:
DOI: https://doi.org/10.1023/A:1010672618269